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Postmortem IgE determination in coronary artery disease 
Abstract 
Allergic inflammation is thought to play a role in atherogenesis and atherosclerotic disease 
progression. IgE may activate mast cells and macrophages located within atheromatous 
lesions, which may contribute to local inflammation and disease progression. On the other 
hand, increased IgE levels in individuals with acute myocardial infarction might also be the 
consequence of immunological reactions to damaged coronary arteries or myocardium. In 
this study, total IgE and mast cell tryptase were measured in a series of forensic autopsy 
cases showing various degrees of coronary artery disease, in order to correlate laboratory 
results with morphological findings and compare them to conclusions reported in the 
clinical setting. A total of 84 subjects were selected and two study groups were 
retrospectively formed, a non-allergic, cardiac death group (42 cases) and a non-allergic, 
non-cardiac control group (42 cases). Our findings indicated that a portion of acute 
coronary syndromes and coronary deaths characterized by coronary atherosclerotic lesions 
of various severities are also characterized by increased total IgE and mast cell tryptase 
levels, thus corroborating the data previously reported in both clinical and forensic 
literature on this topic as well as the necessity of combining morphological investigations 
focusing on the heart and coronary arteries with biochemical analyses. 
Keywords: Coronary Artery Disease; IgE; Postmortem Biochemistry; Forensic; Autopsy 
Introduction 
Inflammation has been shown to play a significant role in atherosclerosis and 
atherosclerotic cardiovascular disease development. Atheromatous lesions are 
characterized by inflammatory cell infiltrates, including macrophages, lymphocytes, and 
mast cells as well as others. Cytokines, chemokines, proinflammatory mediators, 
proteases, and other products of these cells are likely involved in lesion development and 
progression. In addition, a special type of inflammation (allergic inflammation) is thought 
to play a role in atherogenesis and atherosclerotic disease progression [1,2]. 
Mast cell accumulation has been noted in the shoulder regions of coronary atheromatous 
lesions and at the actual sites of coronary plaque erosion or rupture. Based on these 
findings, mast cell activation has been proposed as one of the mechanisms linking allergic 
inflammation with atherosclerotic disease progressions [1,3-8].  
Indeed, numerous biological and clinical studies have postulated the existence of a 
potential relationship between IgE-induced mast cell degranulation and coronary artery 
disease. Elevated total IgE levels have been found in individuals with myocardial 
infarction, suggesting a direct role of IgE, atopy, allergy, and mast cell degranulation in the 
process [2,3,9]. 
IgE may activate mast cells and macrophages located within atheromatous lesions by 
binding to high and low affinity FcεRI and FcεRII receptors situated on the surface of these 
cells. This would therefore activate inflammatory mediator release, which would in turn 
lead to local inflammation, immunological reaction, local IgE-mediated response, and 
atheromatous lesion progression. However, higher IgE in individuals with acute myocardial 
infarction might also be the consequence of immunological reactions due to damaged 
coronary arteries or myocardium. Thus, findings potentially linking IgE, atopy, and allergic 
inflammation to atherosclerotic cardiovascular disease in humans cannot be clearly 
established and have been conflicting [1-3,5,8-10]. 
In the forensic setting, Edston and van Hage-Hamsten [5] measured mast cell tryptase and 
total serum IgE in 29 cases of sudden death from coronary artery thrombosis and 27 control 
cases. Although no statistical difference in mast cell tryptase and total IgE in serum 
between the groups, they documented 20% of coronary deaths had elevated IgE values 
(higher than 200 kU/l) compared to only 8% in the control group. They also observed higher 
mast cells within coronary artery walls in cardiac deaths. Apart from this study, the 
forensic literature has limited reports on mast cell tryptase and total serum IgE in 
atherosclerotic cardiovascular disease. 
The presented study compared postmortem total IgE and mast cell tryptase collected from 
femoral blood between autopsy cases with various degrees of coronary artery 
atherosclerosis and cases control without coronary artery atherosclerosis. 
Material and methods 
Study design and study populations 
A 10-year, case controlled, retrospective study between 2008 and 2018 (inclusive) was 
performed. All selected cases originated from forensic practice and underwent forensic 
investigations as requested by local inquiring authorities (the public prosecutor). 
Postmortem biochemical analyses (IgE and mast cell tryptase determination) were 
performed as part of routine forensic investigations. All forensic autopsies were jointly 
performed by two forensic pathologists (at least one board-certified), as in accordance 
with both local standards and international guidelines for medicolegal cases.  
Case and control selection 
Cases where the postmortem interval (defined as the interval between death and femoral 
blood sampling) did not exceed 48 hours, no history of atopy and full complete autopsy 
performed including histology, toxicology, and postmortem biochemical analyses on 
femoral blood (IgE and mast cell tryptase determination) were initially identified.   
The study was designed such that the same number of cases were used for both case and 
control group and within each group having an equal spread of disease severity. A total of 
84 cases (71 males and 13 females), with a mean age of 49.6 years (range 19-58 years), 
were identified. The cases were initially divided into two groups of equal numbers. The 
study group (42 cases) was non-allergic cardiac, the control group (42 cases) was non-
allergic non-cardiac deaths. 
Non-allergic cardiac death group (n=42) 
14 non-allergic, cardiac deaths were apparently healthy individuals who died suddenly in 
the presence of witnesses, with minimal or no coronary atherosclerosis. Autopsies and 
histology failed to reveal plaque ruptures, plaque hemorrhages or luminal thrombi. Some 
degree of coronary atherosclerosis consisting of lipid plaques was sporadically observed. 
Based on the results of all forensic investigations, the cause of death in all these cases was 
considered cardiac arrhythmia and cardiac arrest in the absence of macroscopic and 
microscopic abnormalities other than minimal coronary artery atherosclerosis.  
Another 14 cases had significant coronary artery atherosclerosis, coronary artery 
calcifications, and severe luminal narrowing as well as myocardial fibrosis of various 
degrees, without evidence of acute coronary thrombosis or myocardial infarction. 
Autopsies and histology revealed coronary atherosclerotic plaques leading to partial or 
complete luminal stenosis as well as various extents of myocardial fibrosis. The presence 
of ruptured plaques and luminal thrombi was histologically excluded in all cases. In 
addition, mast cell accumulation and other inflammatory cells were noted within 
atherosclerotic plaques. Based on the results of all forensic investigations, the cause of 
death in all these cases was determined to be cardiac arrest due to severe coronary artery 
atherosclerosis and myocardial fibrosis.  
The last 14 cases of this group concerned individuals with significant coronary artery 
atherosclerosis, acute coronary thrombosis, and acute myocardial infarction. Autopsies and 
histology revealed ruptured plaques with acute, superimposed luminal thrombi. 
Accumulation of mast cells and other inflammatory cells was noticed within 
atherosclerotic plaques. The cause of death was attributed to cardiac arrest due to 
myocardial infarction in all these cases. 
Non-allergic non-cardiac death (n=42) 
The 42 non-allergic, non-cardiac deaths selected for the control group consisted of 21 
cases of hanging as cause of death and 21 of intracranial gunshot wounds. All these were 
males and had minimal or no coronary artery atherosclerosis at autopsy.  
Postmortem investigations and sample collection 
At autopsy the hearts were sectioned either before or after fixation in 10% neutral 
buffered formalin. The major epicardial coronary arteries were either serially sectioned at 
approximately 2-3 mm intervals or longitudinally sectioned intact on the heart. In selected 
cases, segments of interest were removed from the heart and retained for decalcification 
if needed before paraffin processing. 
Conventional histology included haematoxylin-eosin (HE) stain of the brain, heart, 
coronary arteries, lung, liver, and kidneys. HE stain was performed after tissue fixation in 
formaldehyde. 
Sections of the left and right heart ventricles were examined for evidence of ischemia or 
infarction. Full thickness areas involving the left anterior ventricle, the lateral free wall of 
the left ventricle, left posterior ventricle, interventricular septum and right anterior 
ventricle were systematically sampled.  
In selected cases, coronary arteries (with or without thrombi) were serially embedded in 
paraffin and divided into segments maintaining proximal-to-distal orientation. Histological 
sections were prepared at three different, equally spaced levels to best identify plaque 
rupture sites. Routine histology stains for heart tissues and coronary arteries included HE 
and Masson’s trichrome. 
Peripheral blood from femoral veins was systematically collected as soon as possible upon 
arrival of the bodies at the morgue and prior to autopsy. Blood samples were drawn by 
aspiration with sterile needles after clamping the vein(s) at the proximal end and lifting 
the lower limb(s) for several minutes. Samples were stored in preservative free gel serum 
separator tubes that were centrifuged immediately post collection at 3000 g for 15 min. 
After centrifugation, the separated supernatant (postmortem serum) was collected and 
stored in preservative free tubes. Postmortem serum samples were transferred to the 
laboratories immediately post collection. When analyses were delayed, samples were 
stored at - 20°C. 
Laboratory assays 
Biochemical investigations systematically included mast cell tryptase and total IgE 
measurement in postmortem serum from femoral blood using a commercial fluoroenzyme 
immunoassay method (Pharmacia & Upjohn, Fisher Scientific, Thermo Fisher Scientific, 
Pittsburgh, PA, USA).  
For the purpose of this study, increased total IgE in postmortem serum from femoral blood 
was defined as exceeding the highest upper limit of the clinical reference value indicated 
by the clinical laboratory where the analysis was performed (5-50 kU/l). 
Analogously, increased mast cell tryptase in postmortem serum from femoral blood was 
defined as exceeding the highest upper limit of the clinical reference value indicated by 
the clinical laboratory where the analysis was performed (13 ng/ml). Detection limit was 
below 2ng/ml. 
Statistical analyses 
Data were analyzed by using Greaph Pad Prism (Graph Pad Software Inc.). Postmortem 
serum total IgE and tryptase levels among groups were compared using non-parametric 
tests. Statistical significance was set at p < 0.05. 
Ethical issue 
All relevant ethical issues were identified and discussed with the local Ethical Committee. 
All cases included in this study underwent forensic autopsies as requested by the inquiring 
authorities. Postmortem serum samples are routinely collected during autopsy for 
toxicological and/or biochemical purposes in our facility. Moreover, postmortem 
biochemical analyses are routinely performed as part of forensic investigations. All 
biological samples were anonymized prior to analysis and analyzed in the same laboratory. 
No ethical approval was necessary to perform biochemical analyses in the collected cases. 
Results 
In non-allergic cardiac death cases with minimal or no coronary artery atherosclerosis, 
postmortem serum total IgE levels were lower than the clinical reference value in 12 out of 
14 cases.  
Total IgE ranged between 11 and 48 kU/l (in the 12 negative cases). Two cases had total IgE 
of 289 kU/l and 316 kU/l (the 2 positive cases were a 46-year-old male and a 51-year-old 
female). Postmortem serum mast cell tryptase levels were lower than clinical reference 
values in all cases included in this group. 
In non-allergic cardiac death cases with significant coronary artery atherosclerosis but 
without evidence of acute coronary thrombosis/acute myocardial infarction, postmortem 
serum total IgE levels were lower than the clinical reference value in 12 out of 14 cases.  
Total IgE values ranged between 13 and 44 kU/l (in the 12 negative cases). Two cases had 
IgE of 351 kU/l and 442 kU/l (the 2 positive cases were both males, 49 and 55 years of age 
respectively). Postmortem serum tryptase levels were lower than the clinical reference 
value in 13 out of the 14 cases. The only mast cell tryptase positive case (value 35 ng/ml) 
was observed in the case that had total IgE values at 442 kU/l (55-year-old male). 
Microscopy performed on spleen samples in this case did not show any evidence of mast 
cell infiltration or degranulation. 
In the group of individuals with significant coronary artery atherosclerosis, acute coronary 
thrombosis, and acute myocardial infarction, postmortem serum total IgE levels were 
lower than the clinical reference value in 11 out of 14 cases. Total IgE values ranged 
between 9 and 49 kU/l (in the 11 negative cases). Three cases had IgE of 111 kU/l, 241 kU/
l, and 264 kU/l (these 3 positive cases were a 39-year-old male, a 43-year-old male, and a 
47-year-old female). Postmortem serum tryptase levels were lower than the clinical 
reference value in 12 out of the 14 cases. The two mast cell tryptase positive cases (values 
39 ng/ml and 41 ng/ml) were observed in those cases that had total IgE values at 241 kU/l 
and 264 kU/l (the 43-year-old male and 47 year old female). A tryptase level of 12 ng/ml 
was noted in the male case with 111kU/l. 
Globally considered, these findings revealed postmortem serum total IgE levels were 
higher than the clinical reference value in 7 out of 42 cases (17%) and mast cell tryptase 
levels higher than the clinical reference value in 3 out of 42 cases (7%). 
Non-allergic, non-cardiac death cases had postmortem serum total IgE levels lower than 
the clinical reference value in 39 out of 42 cases. Total IgE values ranged between 8 and 48 
kU/l. In 3 cases out of 42 (7%), IgE levels were at 55, 62 and 98 kU/l (three males of 51, 35 
and 29 years of age respectively). Postmortem investigations revealed mild coronary artery 
atherosclerosis in these three cases (51-year-old male, total IgE 55 kU/l, hanging) and 
minimal coronary artery atherosclerosis consisting of lipid plaques exclusively (35-year-old 
male, total IgE 62 kU/l, hanging, and 29 year-old male with total IgE 98 kU/l, gunshot 
wound). Postmortem serum mast cell tryptase levels were not increased in any of these 
cases. In addition, microscopy performed on spleen samples failed to show any evidence of 
mast cell infiltration or degranulation. 
Statistically speaking, the highest postmortem serum total IgE values were observed in the 
group of individuals with significant coronary artery atherosclerosis without evidence of 
acute coronary thrombosis/acute myocardial infarction (351 kU/l and 442 kU/l). 
Within the limits of the few IgE and tryptase positive cases observed in the group of 
cardiac deaths and controls, there was a statistically significant difference in total IgE 
concentrations between cardiac death cases and controls (17% versus 7% with a mean value 
of 288 kU/l versus 71 kU/l). As stated above, no statistics could be performed concerning 
mast cell tryptase levels since tryptase positive cases were observed exclusively in the 
cardiac death group, with slightly higher tryptase levels in those individuals with acute 
myocardial infarction. 
Discussion 
Atopy is defined as a familiar or personal propensity to develop IgE antibodies against 
common environmental allergens. It is also defined as the leading clinical correlation of 
increased IgE levels and may typically manifest in the form of atopic eczema (atopic 
dermatitis), allergic rhinitis, allergic conjunctivitis, and allergic asthma. Atopy and allergy 
are not synonyms, in that atopic individuals may not necessarily develop one or more 
allergic diseases against specific allergens [3,11]. 
Over the past decades, numerous investigations of varying types have suggested the 
existence of possible links between atopy/allergic inflammation, high serum IgE, coronary 
artery atherosclerosis development, and acute coronary syndromes. Most of these studies 
were performed on live subjects, while there is a great paucity in the postmortem/forensic 
literature on this topic [12]. 
The first ever study to assess a potential relationship between total IgE and ischemic heart 
disease was published by Criqui et al. [13]. These authors performed a cross-sectional, 
population-based study including 262 men and 315 women aged between 38 and 82 years. 
These researchers found that men with a previous history of acute myocardial infarction 
had increased concentrations of IgE in serum. 
Another study was then carried out by Szczeklik et al. [8] that included 116 consecutive 
patients with coronary artery disease. 100 cases consisted of patients with recent acute 
myocardial infarction, and 16 cases of individuals with acute coronary insufficiency 
without any evidence of recent myocardial infarction. They found that patients with acute 
myocardial infarction had increased levels of IgE on hospital admission and that IgE 
continued to rise during the first week after infarction. In addition, patients with high 
initial IgE levels (higher than 200 IU/ml) prior to infarction had greater increases in IgE 
levels after infarction. These cases also had lower severe complication frequency than 
those with initial IgE levels below 200 IU/l, possible suggesting that patients with high IgE 
levels might be protected against complications of infarction. Lastly, in individuals with 
acute coronary insufficiency without any evidence of recent myocardial infarction, serum 
IgE remained unchanged. 
The findings obtained by Szczeklik et al. [8] were subsequently confirmed by Kormaz et al. 
[14] and Erdogan et al. [15], among others. These authors had analogous results in 
individuals with myocardial infarction and unstable angina pectoris.   
Subsequent investigations by Szczeklik et al. [16-23] found significantly increased total 
serum IgE levels in patients with sudden cardiac arrest upon hospital admission (compared 
to patients without cardiac arrest upon admission), as well as increased total serum IgE 
levels after coronary artery bypass grafting. Increased serum total IgE in these patients has 
been suggested as the consequence of inflammatory reactions to coronary artery or 
myocardial damage. However, the authors explained that atopic patients prone to IgE-
mediated mast cell activation might appear to be protected against sudden cardiac death 
after myocardial infarction due to a mild haemostatic imbalance, similar to that produced 
by aspirin. This imbalance would be shown by moderately longer bleeding times, depressed 
platelet aggregability, and delayed thrombin generation in clotting blood. The late 
appearance of this latter would delay clot formation inside a critically obstructed coronary 
artery and these mechanisms, among others, might thus protect atopic patients against 
sudden cardiac death associated with occlusive coronary thrombosis. 
It must be highlighted that data on haemostatic alterations in atopic subjects are sparse 
and somewhat conflicting. Bleeding time may be prolonged in patients with atopic 
diseases, possibly associated to complex heparin-tryptase released by activated mast cells 
that may reduce platelet activity and exert anticoagulant properties. On the other hand, 
mast cells produce and secrete mediators that might have prothrombotic properties. This 
might result in reduced anti-coagulant activity at the inflammation site. Nastalek et al. [6] 
performed a study involving 130 consecutive patients suffering from atopic dermatitis in 
order to investigate fibrin clot characteristics. The authors observed reduced clot 
permeability, prolonged fibrinolysis time, faster fibrin polymerization, higher thrombotic 
mass, and thicker fibers in these patients. These features are known to be linked to 
prothrombotic tendencies.  
Despite exhaustive studies carried out by several research teams, the relationship between 
atopy, allergy, total serum IgE, atherosclerosis, coronary artery disease, and acute 
coronary syndromes is still far from clear [24-29]. 
Wang et al. [9] studied 982 subjects consecutively admitted to several hospitals with 
suspected chronic heart disease. These included 207 individuals with acute myocardial 
infarction, 255 with unstable angina, 247 with stable angina, and 273 control cases with no 
or less than 50% luminal coronary artery narrowing. These authors observed higher total 
serum IgE levels in those with coronary artery disease compared to unaffected individuals. 
The highest levels of IgE were measured in patients with myocardial infarction, followed 
by those with unstable angina, and then by those with stable angina. 
Sinkiewicz et al. [30] measured total serum IgE in a study population including 80 patients 
with acute myocardial infarction, 58 patients with troponin-negative acute coronary 
syndrome, 57 patients with stable angina pectoris with negative personal and family 
history of allergies, as well as in a control population including 39 healthy, age-matched 
individuals. They observed significantly increased concentrations of serum IgE in patients 
suffering from any form of ischemic heart disease, compared to the control group of 
healthy individuals. Changes in IgE serum levels on the first, seventh, fourteenth, and 
fortieth day post myocardial infarction did not show any significant difference. A gender 
difference was observed inasmuch as serum IgE levels were significantly higher in males 
with acute myocardial infarction than females. 
Jaramillo et al. [1] carried out a retrospective study on a U.S. population and analyzed 
data of allergen-specific and total IgE obtained from 4002 adult participants. The aim of 
the study was to investigate the relationship between atopy and past myocardial 
infarction. These authors found that serum IgE levels were inversely related to myocardial 
infarction, independent of multiple coronary risk factors. 
Non-significant differences in serum IgE were noticed by Koltowski et al. [31] in a study 
that compared 52 consecutive patients with ST segment elevation myocardial infarction 
(34 individuals) and unstable angina or myocardial infarction with no ST segment elevation 
(18 individuals). 
Further evidence supporting a possible relationship between atopy, allergy, atheromatous 
disease, and acute cardiovascular events come from the literature on the so-called Kounis 
syndrome, which combines acute coronary syndromes with conditions associated with mast 
cell activation [12,32]. 
Kounis syndrome is defined as the occurrence of acute coronary syndromes (coronary 
spasm, acute myocardial infarction, and stent thrombosis) with conditions associated with 
mast cell and platelet activation, involving interrelated and interacting inflammatory cells 
such as macrophages and T-lymphocytes. Kounis syndrome occurs in the setting of 
hypersensitivity reactions and is caused by the inflammatory mediators released by the 
involved inflammatory cells during a reaction. Although mast cells are numerically inferior 
in this inflammatory cascade, it has been emphasized that they play a decisive role in the 
process. Indeed, mediators released by activated mast cells can induce coronary artery 
spasm, plaque rupture, and thrombosis, leading to a clinical picture of Kounis syndrome. 
On the other hand, all the cells involved in the process activate and co-activate each 
other, creating a sort of “vicious circle of inflammation” [12,33-42]. 
Three variants of Kounis syndrome have been described thus far: in the type I variant, 
coronary spasm in normal or nearly normal coronary arteries associated with 
hypersensitivity reaction can progress to myocardial infarction. In type II variant, 
preexisting atheromatous disease combined with hypersensitivity reactions can result in 
acute myocardial infarction. In type III variant, hypersensitivity reactions in individuals 
with any implanted coronary stent component can result in intrastent thrombosis [31]. 
Kounis syndrome has been postulated to represent a final mast cell-related trigger 
pathway, possibly shared between allergic and non-allergic coronary syndromes. This 
hypothesis would be supported by several lines of evidence as well as by the fact that 
activated mast cells have been found in the shoulder regions of atheromatous lesions and 
actual plaque erosion or rupture sites in patients after acute coronary syndrome or 
myocardial infarction [12,43]. 
Still, it remains unclear and unexplained whether the elevated IgE levels found in 
individuals with acute coronary syndromes are indicative of their participation coronary 
event development or, on the contrary, they are increased following the inflammatory 
reaction sustained by tissues damaged during the event. In essence, the question remains 
as to whether increased IgE levels cause acute coronary events or are caused by them [10]. 
This study was carried out to examine IgE and tryptase in the deceased population. Our 
findings are clearly in agreement with data previously reported in both clinical and 
forensic literature on this topic, i.e. that a portion of acute coronary syndromes and 
coronary deaths characterized by coronary atherosclerotic lesions of various severities 
(ranging from simple lipid plaques to ruptured plaques with superimposed acute thrombi 
and myocardial infarction) are also characterized by increased total IgE levels (in an 
apparently higher proportion than those observed in individuals with other causes of 
death) and increased mast cell tryptase levels (higher than the clinical reference values, in 
the absence of any signs suggesting anaphylaxis as the cause of death). 
We wish to emphasize that increased postmortem serum total IgE and mast cell tryptase 
(possible suggesting mast cell activation preceding acute coronary syndrome) cannot be 
systematically observed in coronary atherosclerosis disease, at least where the 
postmortem setting is concerned, as previously highlighted by other research teams [5, 
43]. 
That notwithstanding, the findings summarized in this paper seem to provide further 
confirmation of the necessity of combining morphological investigations (focusing on the 
heart and coronary arteries) with biochemical analyses (focusing on mast cell tryptase and 
total IgE) in all those deaths characterized by coronary atherosclerosis disease of varying 
importance that forensic pathologists may routinely encounter. This combined approach 
could be of interest in forensic pathology and useful in considering the role allergic 
inflammation may play in the causal process of death in specific (cardiac) situations. 
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